GraphWear Technologies is a technology company.
GraphWear Technologies has raised $4.0M across 1 funding round.
GraphWear Technologies has raised $4.0M in total across 1 funding round.
GraphWear Technologies has raised $4.0M in total across 1 funding round.
GraphWear Technologies's investors include Mission BioCapital.
GraphWear Technologies is a San Francisco-based startup founded in 2015 that develops non-invasive wearable sensors using graphene-enhanced nanotechnology to monitor chronic conditions like diabetes, dehydration, and fat burning without needles, blood, or urine tests.[1][3] The company primarily builds a continuous glucose monitoring (CGM) platform that measures glucose levels through sweat analysis, targeting people with Type 1 and Type 2 diabetes, athletes, consumers, and patients needing real-time health tracking.[2][4] It solves the problem of painful, invasive diagnostics by providing accurate, painless alternatives, with a focus on glucose management to improve quality of life; the firm has raised $24.7M total funding, including a $20.5M Series B in 2023 led by Mayfield, signaling strong growth momentum amid clinical trials for FDA clearance.[2][4]
GraphWear was co-founded in 2015 by Saurabh Radhakrishnan and Rajatesh Gudibande, who aimed to revolutionize chronic disease monitoring by leveraging sweat as a non-invasive proxy for blood biomarkers, given its diluted bio-information content.[1][3][4] The idea emerged from nanotechnology expertise to create flexible sensors tapping into sweat for real-time data, initially prioritizing professional athletic monitoring before expanding to consumer wearables and patient care.[1] Early traction included feasibility studies validating sensor accuracy against blood draws, participation in Plug and Play's startup ecosystem, and a pivot to needle-free CGM, culminating in the 2023 Series B funding to fuel clinical trials and team expansion with hires like Dana Cambra and Woody Scal.[1][2][4][5]
GraphWear rides the wearable healthtech and non-invasive diagnostics trend, fueled by rising diabetes prevalence (half of U.S. Type 1 patients use CGMs, lower globally) and demand for painless, scalable monitoring amid aging populations and chronic disease burdens.[4] Timing aligns with post-pandemic telehealth acceleration and sensor miniaturization advances, where market forces like CGM adoption (e.g., via Abbott, Dexcom) create openings for needle-free disruptors to capture underserved Type 2 and global markets.[2][4] It influences the ecosystem by pushing nanotech into consumer medtech, partnering with accelerators like Plug and Play, and enabling data-driven health insights that could integrate with AI analytics for predictive care.[1][4]
GraphWear is poised for FDA clearance in 2026 via ongoing trials, potentially launching commercial CGM wearables and expanding to multi-biomarker detection for cholesterol, cancer, and beyond, backed by recent hires and funding.[2][4][5] Trends like AI-enhanced wearables, global diabetes growth, and regulatory tailwinds for non-invasives will shape its path, evolving its influence from niche innovator to mainstream health platform provider. This positions GraphWear to transform chronic care much like early CGMs did, delivering the painless monitoring revolution it promised from day one.[3][4]
GraphWear Technologies has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series A in April 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2018 | $4.0M Series A | Mission BioCapital |